ER, PR and HER2 immunohistochemistry, however, is not performed routinely in the UK on DCIS cases as per the NHSBSP breast reporting guidelines and therefore information on receptor status of DCIS/microinvasion within the Sloane Project was only available for a minority of cases. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.